UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
6,876.00-104.00 (-1.49%)
At close: 4:27PM GMT
Sign in to post a message.
  • O
    Sponsored post:
    AstraZeneca PLC could have a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor. Check the disclaimer on the landing page. Meanwhile, these other companies are said to enable more efficient use of materials, improve product quality and safety, reduce work time, and reduce labor costs. Could these give businesses a potentially quicker return? What do you think? Share your ideas here
    Learn Who Is Potentially Using Cutting Edge Solutions to Create the Next Generation of Robotics and Automation
    Learn Who Is Potentially Using Cutting Edge Solutions to Create the Next Generation of Robotics and Automation
  • J
    Article “Why AstraZeneca vaccine approval in Canada may open more doors”

    Dr. Supriya Sharma, Health Canada's chief medical adviser, said the key number across all of the clinical trials for those who received AstraZeneca's product was zero — no deaths, no hospitalizations for serious COVID-19 and no deaths because of an adverse effect of the vaccine.
  • S
    San Diego Mike
    Patience grasshopper. AZN's Covid vaccine clinical trials have been a total cluster f%@&, yet it continues to be the leader providing the world. Positive results out of Scotland have just convinced the French to use on over 65's. With the terrible PR up to now AZN has been reluctant on providing information on the ongoing trials in the U.S. until the results are complete. If the U.K. is any indication the U.S. final results should be positive news. Expect to hear more on the U.S. results before the end of March with a filing for emergency use in April if not sooner. Worldwide manufacturing should be almost fully ramped up by then and the AZN/Oxford vaccine will be the international winner.
  • G
    Gary R.N.
    If AZN stays 48.50 I'll buy more with the 1.400 dollar stimulus check!
    From Gary R.N.
  • C
    bought this leading vaccines stock in Nov. and spiral downward since. My thinking is the Bill Gates and company patented vaccines had the edge in the pharma mafia 💉
  • J
    Down 5% on a large chunk of stock. Will be holding until it comes back to plus 5%. I think this will take between 1 to 3 months. This is a solid company down 13% in a year with very positive results.
    They are not managing their PR very well and there is too much emphasis on the vaccine, but at some point this will pass.
  • Q
    Insider Buying: AZN insiders have bought more shares than they have sold in the past 3 months.
  • P
    If it dips today I am going buy more - we are just a few weeks out from AZN publishing phase 3 clinical trials for US - while this will not create big market for vaccine in US, positive press could create more global demand. Hoping this trial will show its more than than 80% effective after one dose.

    Like to think they are not rushing submitting for emergency US FDA approval because this study will undo any concerns about dosing or previous studies. Critical to get this right.

    Second they have been working on variants since December which means they might have some news soon on that front - recent interview they said fall but this could be sooner

    Finally, Britain has now administered a first dose of COVID-19 vaccine to more than 20 million people & I expect more studies will soon be released - Reuters posted this today - LONDON, March 1 (Reuters) - The Pfizer and AstraZeneca vaccines are more than 80% effective at preventing hospitalisations from COVID-19 in those over 80 after one dose of either shot, Public Health England (PHE) said on Monday, citing a pre-print study.
  • P
    There is a Bloomberg article worth reading - Vaccine Stocks Drop With J&J Set to Release Third U.S. Shot - don't be surprised if we see another dip for a few days. On the upside - AstraZeneca Plc late-stage results from a U.S. trial are expected within the next few weeks.
  • C
    I think we will see that the efficacy of the AZN vaccine confirmed to be nearer 90% when the trials results for the 1/2 + 1 dose regime are in.
    However, it would behoove AZN and Oxford to get on ASAP with adapting the vaccine to the SA variant.
  • r
    Also one hour ago news
    Malaysia approves Sinovac, AstraZeneca COVID-19 vaccines for use
  • T
    Sounds like articles from this morning show the real world data that our COVID-19 vaccine is working in older people. great news
  • S
    Sir Royston
    Thailand begins vaccine program using AZN. Meanwhile, senior German immunologist urges Germany to allow AZN vaccine to over 65 year-olds.
  • N
    AstraZeneca COVID-19 vaccine 'not recommended' in people 65 and older: NACI
  • E
    Can someone help me understand how come share price is 10% below the pre covid jan-20 price? I understand the covid vaccine sales do not target profit making during pandemy, but still it should not harm the company... thanks
  • s
    25% of the population is unvaccinated children would you take a vaccine that would probably result in 3 in 10 potentially getting covid. The answer is no. The Pfizer Moderne vaccine provide 94/95% efficacy against 70%. The only reason the govt are using this is it is the cheapest vaccine out there. AstraZeneca/Oxford are not going to make a penny out of this once the public understands the options.
  • S
    Sir Royston
    Public health Scotland research shows that after 4 weeks of first AZN vaccine, hospital admissions reduced by a staggering 94%.
  • A
    In the press it says they do not make a profit out of the Vaccines can some one tell me if this is correct.
  • r
    this is a solid company people. a buy and hold type, there will be no rocket ride, but earnings will keep it up where it is now ( at worst) and toward $60 topping out. I hope you all made $$ and are happy to stay for good dividends in the years ahead.
  • J
    AZN sold its shares of Moderna when the stock went up. Is this good or bad?

    AstraZeneca (AZN.L) has sold its entire 7.7% stake in Moderna for more than $1 billion, after the U.S. biotechnology company’s shares soared following the success in producing its COVID-19 vaccine.